Iwan Zimmermann is one of the founders and Chief Scientific Officer of Linkster Therapeutics.

Iwan has over 12 years of experience with single domain antibodies and the biology of ion channels and transporters. Prior to co-founding Linkster Therapeutics, Iwan conducted research as platform leader for smart library design and antibody discovery at the University of Zurich. He co-invented the Flycode and Sybody technologies and proved successful as a team player and project leader in a large number of collaborative early drug portfolio projects with pharmaceutical companies worldwide.  

Iwan obtained his master and PhD degrees in Biochemistry at the University of Zurich. In 2018, he was awarded the UZH Bioentrepreneur fellowship program.